SCHEMBL4885704

SCHEMBL4885704

Cc1ccc(NC(=O)c2nccnc2C(=O)O)nc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.64
RAB9A P51151 6/20 0.58
MAPT P10636 3/20 0.58
KDM4E B2RXH2 4/20 0.57
ALDH1A1 P00352 3/20 0.57
SORT1 Q99523 1/20 0.54
NPC1 O15118 6/20 0.52
TP53 P04637 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
GLA P06280 1/20 0.52
GAA P10253 1/20 0.52
HSD17B10 Q99714 1/20 0.52
PKM P14618 1/20 0.52
POLB P06746 1/20 0.50
HCRTR1 O43613 1/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
KDM4A O75164 1/20 0.48
GRM5 P41594 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5233290 0.82 RAB9A (0.51) KMT2ARAB9AMAPTKDM4EALDH1A1
SCHEMBL3001084 0.82 KMT2A (0.60) KMT2ARAB9AALDH1A1SORT1NPC1
SCHEMBL29738591 0.82 KMT2A (0.60) KMT2ARAB9AALDH1A1SORT1NPC1
SCHEMBL29738593 0.82 KMT2A (0.60) KMT2ARAB9AALDH1A1SORT1NPC1
SCHEMBL4283746 0.78 NPC1 (0.57) KMT2ARAB9AMAPTKDM4EALDH1A1
SCHEMBL4882810 0.78 KMT2A (0.56) KMT2AMAPTKDM4EALDH1A1
SCHEMBL16885484 0.78 NPC1 (0.57) KMT2ARAB9AMAPTKDM4EALDH1A1
SCHEMBL2636192 0.78 RAB9A (0.78) KMT2ARAB9AMAPTKDM4EALDH1A1
SCHEMBL3529609 0.76 KDM4E (0.72) KMT2ARAB9AMAPTKDM4EALDH1A1
SCHEMBL30281726 0.76 RAB9A (0.68) KMT2ARAB9AMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214533-A1 Cyclic Iminocarbamates And Their Use BAYER HEALTHCARE AG (DE) 2008-09-04 US disclosed
US-20080214533-A1 Cyclic Iminocarbamates And Their Use BAYER HEALTHCARE AG (DE) 2008-09-04 US disclosed
US-20080214533-A1 Cyclic Iminocarbamates And Their Use BAYER HEALTHCARE AG (DE) 2008-09-04 US disclosed
EP-1819701-A1 CYCLIC IMINOCARBAMATES AND USE THEREOF Bayer HealthCare AG (DE) 2007-08-22 EP disclosed
WO-2006058630-A1 CYCLIC IMINOCARBAMATES AND USE THEREOF BAYER HEALTHCARE AG (DE) 2006-06-08 WO disclosed
WO-2006058630-A1 CYCLIC IMINOCARBAMATES AND USE THEREOF BAYER HEALTHCARE AG (DE) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214533-A1 Cyclic Iminocarbamates And Their Use F2, UQCRB, F12 KMT2A 3720/4885RAB9A 2655/4885MAPT 4803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.